Copeptin: A Neuroendocrine Biomarker of Covid-19 Severity

Hammad, Reham; Elshafei, Ahmed; Khidr, Emad Gamil; El-Husseiny, Ahmed A.; Gomaa, Maher H.; Kotb, Hend G; Eltrawy, Heba H; Farhoud, Hesham

doi:10.2217/bmm-2021-1100

Cited by 13 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies found that the circulating copeptin concentrations were higher in patients with the severe coronavirus disease-19 (COVID-19) compared to those in the moderate and mild patients, at admission and during the follow up period [41]. In addition, several recent studies indicated the probability to use copeptin to distinguish between the patients with community-acquired pneumonia and COVID-19 [42].…”

Section: Evidence Of Copeptin In Modulating the Risk Of Pulmonary Dis...mentioning

confidence: 99%

RETRACTED ARTICLE: Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice

Wang

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

As is shown in previous reports, arginine vasopressin (AVP), as one of the most important hormones within circulation in human beings, is of great clinically significance given that it could maintain the body fluid balance and vascular tone. However, the laboratory measurements AVP in daily clinical practice are shown to be difficult and with low accuracy. Concerning on this notion, it is unpractical to use the serum levels of AVP in diagnosing multiple diseases. On the other hand, another key serum biomarker, copeptin, is confirmed as the C-terminal of the AVP precursor which could be released in equal amounts with AVP, resultantly making it as a sensitive marker of arginine vasopressin release. Notably, emerging recent evidence has demonstrated the critical function of copeptin as a clinical indicator, especially in the diagnosis and prognosis of several diseases in diverse organs, such as cardiovascular disease, kidney disease, and pulmonary disease. In addition, copeptin was recently verified to play an important role in diagnosing multiple acute diseases when combined it with other gold standard serum biomarkers, indicating that copeptin could be recognized as a vital disease marker. Herein, in the current review, the functions of copeptin as a new predictive diagnostic and prognostic biomarker of various diseases, according to the most recent studies, are well summarized. Furthermore, the importance of using copeptin as a serum biomarker in diverse medical departments and the impact of this on improving healthcare service is also summarized in the current review.

show abstract

Section: Evidence Of Copeptin In Modulating the Risk Of Pulmonary Dis...mentioning

confidence: 99%

RETRACTED ARTICLE: Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice

Wang

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

show abstract

“…There are data on the predictive ability of mortality in hospitalized patients using a score classification combining peripheral capillary oxygen saturation, albumin, D-dimer, and age ( 20 ). Others, focusing on neuroendocrine biomarkers such as copeptin, found an increase in severe cases ( 21 ). However, there are currently no conclusive data from clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

et al. 2023

View full text Add to dashboard Cite

BackgroundApproximately 13.8% and 6.1% of coronavirus disease 2019 (COVID-19) patients require hospitalization and sometimes intensive care unit (ICU) admission, respectively. There is no biomarker to predict which of these patients will develop an aggressive stage that we could improve their quality of life and healthcare management. Our main goal is to include new markers for the classification of COVID-19 patients.MethodsTwo tubes of peripheral blood were collected from a total of 66 (n = 34 mild and n = 32 severe) samples (mean age 52 years). Cytometry analysis was performed using a 15-parameter panel included in the Maxpar® Human Monocyte/Macrophage Phenotyping Panel Kit. Cytometry by time-of-flight mass spectrometry (CyTOF) panel was performed in combination with genetic analysis using TaqMan® probes for ACE2 (rs2285666), MX1 (rs469390), and TMPRSS2 (rs2070788) variants. GemStone™ and OMIQ software were used for cytometry analysis.ResultsThe frequency of CD163+/CD206- population of transitional monocytes (T-Mo) was decreased in the mild group compared to that of the severe one, while T-Mo CD163-/CD206- were increased in the mild group compared to that of the severe one. In addition, we also found differences in CD11b expression in CD14dim monocytes in the severe group, with decreased levels in the female group (p = 0.0412). When comparing mild and severe disease, we also found that CD45- [p = 0.014; odds ratio (OR) = 0.286, 95% CI 0.104–0.787] and CD14dim/CD33+ (p = 0.014; OR = 0.286, 95% CI 0.104–0.787) monocytes were the best options as biomarkers to discriminate between these patient groups. CD33 was also indicated as a good biomarker for patient stratification by the analysis of GemStone™ software. Among genetic markers, we found that G carriers of TMPRSS2 (rs2070788) have an increased risk (p = 0.02; OR = 3.37, 95% CI 1.18–9.60) of severe COVID-19 compared to those with A/A genotype. This strength is further increased when combined with CD45-, T-Mo CD163+/CD206-, and C14dim/CD33+.ConclusionsHere, we report the interesting role of TMPRSS2, CD45-, CD163/CD206, and CD33 in COVID-19 aggressiveness. This strength is reinforced for aggressiveness biomarkers when TMPRSS2 and CD45-, TMPRSS2 and CD163/CD206, and TMPRSS2 and CD14dim/CD33+ are combined.

show abstract

“…ESR can be used as a helpful sign for differentiating severe disease courses in the first stage to raise the survival of patients with severe COVID-19. Different studies have shown lymphocytopenia predicts the severity of SARS-CoV-2 and can be utilized as a prognostic marker in COVID-19 patients with severe disease [78] , [79] , [80] , [81] . Other researches have found that lymphocytopenia and increased inflammatory cytokines levels in patients with COVID-19 [2] , [75] as well as neutrophil/ cluster of differentiation 8+ (CD8+) T cell proportion and high IL6 levels [82] , [83] as indicators for quick detection of severe COVID-19 patients.…”

Section: Possible Variables Affecting Symptom Variability and Severit...mentioning

confidence: 99%

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions

Abulsoud¹,

El-Husseiny²,

El-Husseiny³

et al. 2023

Biomedicine & Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

Copeptin: A Neuroendocrine Biomarker of Covid-19 Severity

Cited by 13 publications

References 42 publications

RETRACTED ARTICLE: Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice

RETRACTED ARTICLE: Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice

Relevance of TMPRSS2, CD163/CD206, and CD33 in clinical severity stratification of COVID-19

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions

Contact Info

Product

Resources

About